GlassScriptPhysician profile
Norman D Numerof
NPI 1720192776
$415.99
in general payments reported to CMS, 2019-2025
14 companies · $32.53 in 2025
The $32.53 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $174 · 2020: $29.45 · 2021: $15.40 · 2022: $12.48 · 2023: $56.14 · 2024: $96.22 · 2025: $32.53.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $184.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $131.61 | 2019 | |
| Amgen INC. | $69.61 | 2023-2025 | Repatha, Otezla, Evenity |
| Janssen Pharmaceuticals, INC | $29.05 | 2019 | |
| Lucid Diagnostics INC. | $23.46 | 2024 | |
| Abbvie INC. | $19.67 | 2023 | |
| Itamar Medical INC | $19.57 | 2023 | Watchpatone |
| Eisai INC. | $17.89 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $17.87 | 2024 | Airsupra |
| Aimmune Therapeutics, INC. | $17.55 | 2024 | |
| Linus Health, INC. | $17.16 | 2024 | Core Cognitive Evaluation |
| Genentech USA, INC. | $15.40 | 2021 | |
| Sanofi-Aventis U.S. LLC | $13.11 | 2019 | |
| Dexcom, INC. | $12.48 | 2022 | |
| Pfizer INC. | $11.56 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Norman Numerof listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.